

29. West S, Rowbotham D, Xiong G, Kenedi C. Clozapine induced gastrointestinal hypomotility: A potentially life threatening adverse event. A review of the literature. *General Hospital Psychiatry*. 2017;46:32-37.
30. Every-Palmer S, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: An analysis of 102 cases. *The Journal of Clinical Psychiatry*. 2008;69(5):759-768.
31. Richardson N, Greenway SC, Bousman CA. Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review. *Psychiatry Research*. 2021;305.
32. Masopust J, Kopeček M, Protopopová D. Sledování tělesného zdraví u pacientů se závažnými neorganickými duševními poruchami (psychózy, bipolární porucha, depresivní porucha). Doporučené postupy psychiatrické péče Psychiatrické společnosti ČLS JEP. 2020. <https://postupy-pecce-psychiatrie.cz/obecna-psychiatrie/sledovani-telesneho-zdravi>
33. Ronaldson KJ, Fitzgerald PB, Taylor AJ et al: A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. *Australian & New Zealand Psychiatry*. 2011; 45(6): 458–65.
34. Bellissima BL, Tingle MD, Cicović A et al: A systematic review of clozapine induced myocarditis. *International Journal of Cardiology*. 2018; 259: 122–29.
35. Vickers M, Ramineni V, Malacova E, et al. Risk factors for clozapine-induced myocarditis and cardiomyopathy: A systematic review and meta-analysis. *Acta Psychiatrica Scandinavica*. 2022;145(5):442-455.
36. Hosseini SA, Skrzypczak B, Yasaei R, et al. Successful Clozapine Re-Challenge After Suspected Clozapine-Induced Myocarditis. *American Journal of Case Reports*. 2020;21:1-6.
37. Noël M-C, Powell V, Burton L et al: Clozapine-related myocarditis and rechallenge: A case series and clinical review. *Journal of Clinical Psychopharmacology*. 2019; 39(4): 380–85.
38. Ronaldson KJ, Fitzgerald PB, Taylor AJ et al: Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: A case-control study. *Schizophrenia Research*. 2012; 141(2–3): 173–78.
39. de Leon J, Tang Y-L, Baptista T, et al. Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations. *Acta Psychiatrica Scandinavica*. 2015;132(4):242-243.
40. Griffin JM, Woznica E, Gilotra NA, Nucifora FC Jr. Clozapine-Associated Myocarditis: A Protocol for Monitoring Upon Clozapine Initiation and Recommendations for How to Conduct a Clozapine Rechallenge. *Journal of Clinical Psychopharmacology*. 2021;41(2):180-185.
41. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. *Pharmacopsychiatry*. 2018;51(1-02):e1.
42. Hefner G, Shams M, Unterecker S, Falter T, Hiemke C. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. *Psychopharmacology*. 2016;233(9):1695-1705.
43. Whiskey E, Taylor D. Restarting clozapine after neutropenia : Evaluating the possibilities and practicalities. *CNS drugs*. 2007;21(1):25-35.
44. Malik S, Lally J, Ajnakina O, et al. Sodium valproate and clozapine induced neutropenia: A case control study using register data. *Schizophrenia Research*. 2018;195:267-273.
45. Myles N, Myles H, Clark SR, et al. Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations. *Australian and New Zealand Journal of Psychiatry*. 2017;51(10):980-989.
46. Lally J, Malik S, Krivoy A, Whiskey E, Taylor DM, Gaughran FP, Flanagan RJ, Mijovic A, MacCabe JH. The Use of Granulocyte Colony-Stimulating Factor in Clozapine Rechallenge: A Systematic Review. *Journal of Clinical Psychopharmacology*. 2017;37(5):600-604.
47. Lichnovský O, Ustohal L. Vysazení klozapinu z důvodu neutropenie a možnosti jeho opětovného nasazení do medikace. *Psychiatrie*. 2022;4:167-171.
48. Yadav D, Burton S, Sehgal C. Clozapine-induced neutropenia reversed by lithium. *Progress in Neurology & Psychiatry*. 2016;20(3):13-15.
49. Kanaan RA, Kerwin RW. Lithium and clozapine rechallenge: a retrospective case analysis. *The Journal of Clinical Psychiatry*. 2006;67(5):756-760.
50. Kourti, K. Paschalidis, C-M. Platsa, et al. Clozapine Rechallenge with Lithium After Double Induced Neutropenia: A Case Report. *Dialogues in Clinical Neuroscience & Mental Health*. 2019;1(4):150-157.
51. Carmen J, Okafor K, Ike E. The effects of lithium therapy on leukocytes: a 1-year follow-up study. *Journal of the National Medical Association*. 1993;85(4):301-303.
52. Clozapine treatment guidelines https://www.candi.nhs.uk/sites/default/files/Clozapine%20Treatment%20guidelines%20_PHA06_August%202021.pdf
53. Boazak M, Goldsmith DR, Cotes RO. Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be Risky. *The Primary Care Companion for CNS disorders*. 2018;20(6).
54. Béchard L, Morasse-Bégis M, Corbeil O, et al. Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series. *Journal of Clinical Psychopharmacology*. May 2022.
55. Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. *The British Journal of Psychiatry : the journal of mental science*. 2006;188:255-263.
56. Shuman M, Dilich A, Moss L. Never Say Never: Successful Clozapine Rechallenge After Multiple Episodes of Neutropenia. *FOCUS*. 2021;19:66-70.
57. Oloyede E, Blackman G, Whiskey E, et al. Clozapine haematological monitoring for neutropenia: a global perspective. *Epidemiology and Psychiatric Sciences*. 2022;31:e83.